<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03382795</url>
  </required_header>
  <id_info>
    <org_study_id>KUGH17195 (EGFR retreatment)</org_study_id>
    <nct_id>NCT03382795</nct_id>
  </id_info>
  <brief_title>Retreatment With Epidermal Growth Factor Receptor(EGFR) Tyrosine Kinase Inhibitor in EGFR Mutation Positive Patients</brief_title>
  <official_title>Retreatment With 1st Generation EGFR TKIs in Sensitizing EGFR Mutation Positive Non-Squamous Cell Carcinoma Patients Who Previously Treated With EGFR TKI and Cytotoxic Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea University Guro Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chong Kun Dang Pharmaceutical Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Korea University Guro Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this trial, treatment efficacy and safety of retreatment with 1st generation epidermal
      growth factor receptor(EGFR) tyrosine kinase inhibitor(TKI)s(Gefitinib/Erlotinib), will be
      assessed in patients with sensitizing EGFR mutation positive Non-Squamous Cell Carcinoma
      patients who previously treated with EGFR TKI and cytotoxic chemotherapy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed to be multi-center, open-label, single-arm, prospective, phase II
      trial of patient with sensitizing EGFR mutation positive Non-Squamous Cell Carcinoma patients
      who previously treated with EGFR TKI and cytotoxic chemotherapy. Approximately 69 patients
      will be enrolled into the trial, and expected study duration is 24 months from Institutional
      Review Board(IRB) and Korea Ministry of Food and Drug Safety(MFDS) approval date.

      The study drug will be administered orally as one tablet(Gefitinib 250mg/ Erlotinib 150mg)
      once a day until disease progression or manifestation of unacceptable toxicity. The initial
      dose of the study drug daily can be reduced according to dose reduction criteria in protocol.
      A cycle of study treatment is defined as 28 days, and subjects will visit the site every 2
      cycles(56 days).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 14, 2017</start_date>
  <completion_date type="Anticipated">September 13, 2019</completion_date>
  <primary_completion_date type="Anticipated">September 13, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate(ORR) including rage of CR&amp;PR</measure>
    <time_frame>Through study completion (2 years)</time_frame>
    <description>Assessed on based of RECIST 1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival, PFS</measure>
    <time_frame>Through study completion (2 years)</time_frame>
    <description>Progression-free survival (PFS) the time from first dose of the study drug until the date of disease progression or death by any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Through study completion (2 years)</time_frame>
    <description>Overall Survival (OR) the time from first dose of the study drug until the date of death by any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of Adverse Events(including Serious Adverse Events and Adverse Drug Reactions)</measure>
    <time_frame>Through study completion (2 years)</time_frame>
    <description>Assessment on the base of NCI-CTCAE (version 4.03)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">69</enrollment>
  <condition>EGFR Positive Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>EGFR retreat group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EGFR</intervention_name>
    <description>Gefitinib 250mg or Erlotinib 150mg medication, Once-Daily.</description>
    <arm_group_label>EGFR retreat group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males or females ≥ 19 years of age

          2. Non Small Cell Lung Cancer(Non-Squamous Cell Carcinoma) patients who had shown
             clinical benefits (Complete response(CR) or Partial response(PR) or Stable disease(SD)
             ≥6 months) from EGFR-TKIs as first line treatment and developed progressive disease,
             and then received cytotoxic chemotherapy more than 4 cycles and developed progressive
             disease, and then confirmed methionine for threonine at amino acid position 790(T790M)
             negative and sensitizing EGFR mutation positive in Histologic or cytologic specimen.

          3. Patient with at least one measurable lesions according to RECIST v 1.1

          4. Expected life expectancy ≥ 12 weeks

          5. Eastern Cooperative Oncology Group(ECOG) performance status ≤ 2

          6. Patients who have proper hematologic, renal and hepatic functions as follows:

               -  Absolute neutrophil count(ANC) ≥ 1,500/mm³

               -  platelets ≥ 100,000/mm³

               -  Hemoglobin ≥ 9g/dL

               -  Total bilirubin ≤ 1.25 X UNL

               -  Aspartate aminotransferase(AST or SGOT) and alanine aminotransferase(ALT or SGPT)
                  ≤ 3.0 X UNL (if liver metastasis ≤5.0 X UNL)

               -  Alkaline phosphatase ≤ 2.5 X UNL (if liver metastasis ≤5.0 X UNL)

               -  Serum creatinine ≤ 1.5mg/dL

          7. patients who are willing to comply with study procedure and voluntarily provide
             informed consent with signature

        Exclusion Criteria:

          1. Patients who have preexisting or coexisting malignancies in other parts except for
             effectively treated non-melanoma skin cancer, cervical carcinoma in situ(CIS) cervical
             cancer within the last 5 years

          2. Patients with central nervous system(CNS) metastasis

          3. Patients currently receiving palliative radiation therapy or have toxicities from
             radiation therapy at screening.

          4. Patients with clinically active history of interstitial lung disease(ILD), Drug
             induced ILD, Radiation pneumonitis

          5. Patients with clinically significant cardiovascular disease or myocardial infarction
             within the past 12 months.

          6. Patients with active infection or severe systemic disease that are difficult to
             include in this study

          7. Patients who received radiation therapy to target lesion of this study.

          8. Patients who had major operation within 4 weeks before starting the study treatment
             and were not fully recovered.

          9. Patients who were administered other study drugs within 4 weeks before starting the
             study treatment

         10. Males and females of reproductive potential who are not using an effective method of
             birth control and females who are pregnant or breastfeeding or have a positive
             pregnancy test prior to study entry

         11. Patients who are difficult to include in this study in accordance with the
             investigator's judgment

         12. Patients with histories of hypersensitivity to investigational product(IP) or any
             components of the agent

         13. Patients with any of the following genetic predispositions including galactose
             intolerance, Lapp lactase deficiency, lactose intolerance or glucose-galactose
             malabsorption

         14. Patient previously received cytotoxic chemotherapy within 2 weeks of IP administration

         15. Patient received Immunotherapy prior to the study participation

         16. Patients who are difficult to include in this study in accordance with the
             investigator's judgment due to severe adverse effects during previous EGFR TKI
             treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sung Yong Lee, MD, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sung Yong Lee, MD, Ph.D.</last_name>
    <phone>82-2-2626-3030</phone>
    <email>dragonett@naver.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Young Sun Cho</last_name>
    <email>gomtty@daum.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hallym University Sacred Heart Hospital</name>
      <address>
        <city>Anyang</city>
        <state>Gyeonggi-do</state>
        <zip>14068</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seung Hun Jang, MD, Ph.D.</last_name>
    </contact>
    <investigator>
      <last_name>Seung Hun Jang, MD, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pusan National University Yangsan Hospital</name>
      <address>
        <city>Busan</city>
        <state>Gyeongsangnam-do</state>
        <zip>50612</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seong Hoon Yoon, MD, Ph.D.</last_name>
    </contact>
    <investigator>
      <last_name>Seong Hoon Yoon, MD, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>YUN SEONG KIM, MD, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hwasun Hospital</name>
      <address>
        <city>Hwasun</city>
        <state>Jeollanam-do</state>
        <zip>58128</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>In Jae Oh, MD, Ph.D.</last_name>
    </contact>
    <investigator>
      <last_name>In Jae Oh, MD, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Young Chul Kim, MD, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chul Kyu Park, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chungnam National University Hospital</name>
      <address>
        <city>Daegu</city>
        <zip>35015</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeong Eun Lee, MD, Ph.D.</last_name>
    </contact>
    <investigator>
      <last_name>Jeong Eun Lee, MD, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chaeuk Chung, MD, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dong Il Park, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yonsei University Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eun Young Kim, MD, Ph.D.</last_name>
    </contact>
    <investigator>
      <last_name>Eun Young Kim, MD, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeong Mo Lee, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Konkuk University Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05030</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kye Young Lee, MD, Ph.D.</last_name>
    </contact>
    <investigator>
      <last_name>Kye Young Lee, MD, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hee Joung Kim, MD, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>In Ae Kim, MD, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jong Sik Lee, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jae Cheol Lee, MD, Ph.D.</last_name>
    </contact>
    <investigator>
      <last_name>Jae Cheol Lee, MD, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>08308</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seung-hoe Song, MBE</last_name>
      <phone>82-2-2626-1635</phone>
      <email>ssessong@korea.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Sung Yong Lee, MD, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jee Youn Oh, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sang Mi Chung, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://globocan.iarc.fr</url>
    <description>GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012. All cancers (excluding nonmelanoma skin cancer) estimated incidence, mortality and prevalence worldwide in 2012 [Internet]. Geneva: World Health Organization</description>
  </link>
  <link>
    <url>http://www.nccn.org</url>
    <description>National Comprehensive Cancer Network: National Comprehensive Cancer Network(NCCN) Clinical Practice Guidelines in Oncology— Non-Small Cell Lung Cancer, Version 5.2017.</description>
  </link>
  <reference>
    <citation>Janssen-Heijnen ML, Coebergh JW. The changing epidemiology of lung cancer in Europe. Lung Cancer. 2003 Sep;41(3):245-58. Review.</citation>
    <PMID>12928116</PMID>
  </reference>
  <reference>
    <citation>Jemal A, Chu KC, Tarone RE. Recent trends in lung cancer mortality in the United States. J Natl Cancer Inst. 2001 Feb 21;93(4):277-83.</citation>
    <PMID>11181774</PMID>
  </reference>
  <reference>
    <citation>Kinoshita FL, Ito Y, Nakayama T. Trends in Lung Cancer Incidence Rates by Histological Type in 1975-2008: A Population-Based Study in Osaka, Japan. J Epidemiol. 2016 Nov 5;26(11):579-586. Epub 2016 Apr 30.</citation>
    <PMID>27150013</PMID>
  </reference>
  <reference>
    <citation>Dela Cruz CS, Tanoue LT, Matthay RA. Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med. 2011 Dec;32(4):605-44. doi: 10.1016/j.ccm.2011.09.001. Review.</citation>
    <PMID>22054876</PMID>
  </reference>
  <reference>
    <citation>Shin A, Oh CM, Kim BW, Woo H, Won YJ, Lee JS. Lung Cancer Epidemiology in Korea. Cancer Res Treat. 2017 Jul;49(3):616-626. doi: 10.4143/crt.2016.178. Epub 2016 Sep 23.</citation>
    <PMID>27669705</PMID>
  </reference>
  <reference>
    <citation>Jackman DM, Miller VA, Cioffredi LA, Yeap BY, Jänne PA, Riely GJ, Ruiz MG, Giaccone G, Sequist LV, Johnson BE. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res. 2009 Aug 15;15(16):5267-73. doi: 10.1158/1078-0432.CCR-09-0888. Epub 2009 Aug 11.</citation>
    <PMID>19671843</PMID>
  </reference>
  <reference>
    <citation>Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009 Sep 3;361(10):947-57. doi: 10.1056/NEJMoa0810699. Epub 2009 Aug 19.</citation>
    <PMID>19692680</PMID>
  </reference>
  <reference>
    <citation>Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T; North-East Japan Study Group. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010 Jun 24;362(25):2380-8. doi: 10.1056/NEJMoa0909530.</citation>
    <PMID>20573926</PMID>
  </reference>
  <reference>
    <citation>Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Muñoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L; Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012 Mar;13(3):239-46. doi: 10.1016/S1470-2045(11)70393-X. Epub 2012 Jan 26.</citation>
    <PMID>22285168</PMID>
  </reference>
  <reference>
    <citation>Sequist LV, Yang JC, Yamamoto N, O'Byrne K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, Su WC, Bennouna J, Kato T, Gorbunova V, Lee KH, Shah R, Massey D, Zazulina V, Shahidi M, Schuler M. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013 Sep 20;31(27):3327-34. doi: 10.1200/JCO.2012.44.2806. Epub 2013 Jul 1.</citation>
    <PMID>23816960</PMID>
  </reference>
  <reference>
    <citation>Yu HA, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, Pao W, Kris MG, Miller VA, Ladanyi M, Riely GJ. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013 Apr 15;19(8):2240-7. doi: 10.1158/1078-0432.CCR-12-2246. Epub 2013 Mar 7.</citation>
    <PMID>23470965</PMID>
  </reference>
  <reference>
    <citation>Besse B, Adjei A, Baas P, Meldgaard P, Nicolson M, Paz-Ares L, Reck M, Smit EF, Syrigos K, Stahel R, Felip E, Peters S; Panel Members; ESMO. 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease. Ann Oncol. 2014 Aug;25(8):1475-84. doi: 10.1093/annonc/mdu123. Epub 2014 Mar 25.</citation>
    <PMID>24669016</PMID>
  </reference>
  <reference>
    <citation>Asahina H, Oizumi S, Inoue A, Kinoshita I, Ishida T, Fujita Y, Sukoh N, Harada M, Maemondo M, Saijo Y, Dosaka-Akita H, Isobe H, Nukiwa T, Nishimura M; Hokkaido Lung Cancer Clinical Study Group. Phase II study of gefitinib readministration in patients with advanced non-small cell lung cancer and previous response to gefitinib. Oncology. 2010;79(5-6):423-9. doi: 10.1159/000326488. Epub 2011 Apr 8.</citation>
    <PMID>21474967</PMID>
  </reference>
  <reference>
    <citation>Koizumi T, Agatsuma T, Ikegami K, Suzuki T, Kobayashi T, Kanda S, Yoshikawa S, Kubo K, Shiina T, Takasuna K, Matsuo A, Hayasaka M, Morikawa M, Ameshima S. Prospective study of gefitinib readministration after chemotherapy in patients with advanced non-small-cell lung cancer who previously responded to gefitinib. Clin Lung Cancer. 2012 Nov;13(6):458-63. doi: 10.1016/j.cllc.2012.01.006. Epub 2012 Mar 7.</citation>
    <PMID>22402083</PMID>
  </reference>
  <reference>
    <citation>Oh IJ, Ban HJ, Kim KS, Kim YC. Retreatment of gefitinib in patients with non-small-cell lung cancer who previously controlled to gefitinib: a single-arm, open-label, phase II study. Lung Cancer. 2012 Jul;77(1):121-7. doi: 10.1016/j.lungcan.2012.01.012. Epub 2012 Feb 12.</citation>
    <PMID>22333554</PMID>
  </reference>
  <reference>
    <citation>Hata A, Katakami N, Yoshioka H, Fujita S, Kunimasa K, Nanjo S, Otsuka K, Kaji R, Tomii K, Iwasaku M, Nishiyama A, Hayashi H, Morita S, Ishida T. Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: clinical benefit with optimal patient selection. Lung Cancer. 2011 Nov;74(2):268-73. doi: 10.1016/j.lungcan.2011.03.010. Epub 2011 May 6.</citation>
    <PMID>21529987</PMID>
  </reference>
  <reference>
    <citation>Kaira K, Naito T, Takahashi T, Ayabe E, Shimoyama R, Kaira R, Ono A, Igawa S, Shukuya T, Murakami H, Tsuya A, Nakamura Y, Endo M, Yamamoto N. Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer. Lung Cancer. 2010 Apr;68(1):99-104. doi: 10.1016/j.lungcan.2009.05.006. Epub 2009 Jun 21.</citation>
    <PMID>19540616</PMID>
  </reference>
  <reference>
    <citation>Mok TS, Wu Y-L, Ahn M-J, Garassino MC, Kim HR, Ramalingam SS, Shepherd FA, He Y, Akamatsu H, Theelen WS, Lee CK, Sebastian M, Templeton A, Mann H, Marotti M, Ghiorghiu S, Papadimitrakopoulou VA; AURA3 Investigators. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med. 2017 Feb 16;376(7):629-640. doi: 10.1056/NEJMoa1612674. Epub 2016 Dec 6.</citation>
    <PMID>27959700</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2017</study_first_submitted>
  <study_first_submitted_qc>December 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 26, 2017</study_first_posted>
  <last_update_submitted>January 9, 2018</last_update_submitted>
  <last_update_submitted_qc>January 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Korea University Guro Hospital</investigator_affiliation>
    <investigator_full_name>Sung Yong Lee</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Epidermal growth factor receptor tyrosine kinase inhibitor</keyword>
  <keyword>Cytotoxic chemotherapy</keyword>
  <keyword>Epidermal growth factor receptor mutation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitogens</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

